BioNTech SE (BNTX)
Healthcare • Biotechnology
StockNasdaqGSGermanyUS09075V1026
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by BioNTech SE, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 12 Nov 2026 21:00. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 02 Mar 2027 08:00 | -1.77 | — | — | Upcoming |
| 03 Nov 2026 06:00 | 0.76 | 1.76 | +132.2% | Beat |
| 04 Aug 2026 07:00 | -2.08 | -2.22 | -6.8% | Miss |
| 05 May 2026 06:00 | -1.92 | -1.95 | -1.6% | Miss |
| 10 Mar 2026 06:00 | -0.25 | -0.33 | -30.4% | Miss |
| 03 Nov 2025 06:00 | 0.10 | -0.12 | -220.3% | Miss |
| 04 Aug 2025 06:00 | -1.41 | -1.60 | -13.8% | Miss |
| 05 May 2025 06:00 | -2.35 | -1.73 | +26.3% | Beat |
| 10 Mar 2025 06:00 | 0.37 | 1.08 | +188.9% | Beat |
| 04 Nov 2024 06:00 | -1.61 | 0.81 | +150.4% | Beat |
| 05 Aug 2024 06:00 | -2.04 | -3.36 | -64.4% | Miss |
| 06 May 2024 06:00 | -1.35 | -1.31 | +2.9% | Beat |
| 20 Mar 2024 06:00 | 2.45 | 1.90 | -22.5% | Miss |
| 06 Nov 2023 06:00 | -0.67 | 0.67 | +200.5% | Beat |
| 07 Aug 2023 06:00 | -0.73 | -0.79 | -8.6% | Miss |
| 08 May 2023 06:00 | 0.52 | 2.05 | +294.2% | Beat |
| 27 Mar 2023 06:00 | 7.77 | 9.26 | +19.2% | Beat |
| 07 Nov 2022 06:00 | 3.42 | 6.98 | +104.3% | Beat |
| 08 Aug 2022 06:00 | 7.08 | 6.45 | -8.9% | Miss |
| 09 May 2022 06:00 | 9.16 | 14.24 | +55.4% | Beat |
| 30 Mar 2022 06:00 | 7.44 | 12.18 | +63.7% | Beat |
| 09 Nov 2021 06:00 | 10.54 | 12.35 | +17.2% | Beat |
| 09 Aug 2021 07:00 | 7.55 | 10.77 | +42.7% | Beat |
| 10 May 2021 07:00 | 3.64 | 4.39 | +20.5% | Beat |
| 30 Mar 2021 06:00 | -0.29 | 1.57 | +634.9% | Beat |
| 10 Nov 2020 07:00 | -0.40 | -0.88 | -119.3% | Miss |
| 11 Aug 2020 17:00 | -0.32 | -0.38 | -19.5% | Miss |
| 12 May 2020 08:00 | -0.28 | -0.24 | +13.6% | Beat |
| 31 Mar 2020 07:00 | -0.17 | -0.26 | -49.5% | Miss |
| 14 Nov 2019 07:00 | -0.17 | -0.14 | +18.7% | Beat |
Annual results · EUR
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 2.9B | +4.3% | -1.1B | -39.6% | -4.70 | -69.7% | -293M |
| 2024 | 2.8B | -28.0% | -665.3M | -24.2% | -2.77 | -172.3% | -244.6M |
| 2023 | 3.8B | -77.9% | 930.3M | 24.4% | 3.83 | -89.9% | 4.7B |
| 2022 | 17.3B | — | 9.4B | 54.5% | 37.77 | — | 13.2B |
| 2021 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 12 Nov 2026 | 86.70 | 86.87 | 84.80 | 85.03 | -2.99% | 886,021 | |
| 11 Nov 2026 | 87.18 | 87.73 | 86.09 | 87.65 | +0.50% | 765,400 | |
| 10 Nov 2026 | 87.10 | 88.08 | 86.39 | 87.21 | -0.34% | 693,300 | |
| 09 Nov 2026 | 87.76 | 88.78 | 86.56 | 87.51 | 0.00% | 1,142,900 | |
| 06 Nov 2026 | 85.60 | 87.94 | 84.89 | 87.51 | +1.92% | 724,200 | |
| 05 Nov 2026 | 90.83 | 90.88 | 85.80 | 85.86 | -5.34% | 1,190,700 | |
| 04 Nov 2026 | 89.24 | 91.46 | 88.25 | 90.70 | +4.35% | 1,352,800 | |
| 03 Nov 2026 | 89.65 | 89.88 | 86.44 | 86.92 | -0.70% | 1,152,300 | |
| 02 Nov 2026 | 88.20 | 88.74 | 87.20 | 87.53 | -0.73% | 709,800 | |
| 30 Oct 2026 | 89.22 | 90.32 | 87.44 | 88.17 | -1.08% | 631,800 | |
| 1,249 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- BioNTech To Acquire FDA Priority Review Voucher From Scholar Rock For $205M In Cash (opens in a new tab) Benzinga · 10 Nov 2026 08:08
- HC Wainwright & Co. Maintains Buy on BioNTech, Lowers Price Target to $110 (opens in a new tab) Benzinga · 09 Nov 2026 08:40
- Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher (opens in a new tab) 24/7 Wall St. · 06 Nov 2026 16:05
- BioNTech SE 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 04 Nov 2026 23:06
- UBS Maintains Buy on BioNTech, Lowers Price Target to $125 (opens in a new tab) Benzinga · 04 Nov 2026 19:14
- Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $106 (opens in a new tab) Benzinga · 04 Nov 2026 13:59
- Wells Fargo Maintains Overweight on BioNTech, Lowers Price Target to $125 (opens in a new tab) Benzinga · 04 Nov 2026 11:35
- BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet (Rating Downgrade) (opens in a new tab) SeekingAlpha · 04 Nov 2026 09:30
- Evercore ISI Group Maintains Outperform on BioNTech, Lowers Price Target to $110 (opens in a new tab) Benzinga · 04 Nov 2026 09:26
- BioNTech (BNTX) Enters First Global Phase 3 Trial For New Breast Cancer Combo (opens in a new tab) Simply Wall St. · 04 Nov 2026 03:18
- BioNTech SE (BNTX) (Q3 2026) Earnings Call Highlights: Oncology Pipeline Momentum Builds as ... (opens in a new tab) GuruFocus.com · 04 Nov 2026 03:04
- BioNTech Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 03 Nov 2026 18:14
- BioNTech SE (BNTX) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 03 Nov 2026 16:16
- BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update (opens in a new tab) 03 Nov 2026 11:45
- BioNTech Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 03 Nov 2026 10:25
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 87.65 USD
- Market cap
- 21.4B
- Last dividend
- 2.1110 USD · 02 Jun 2022
- Exchange
- NasdaqGS
- Country
- Germany
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
| Ex-dividend date | Per share |
|---|---|
| 02 Jun 2022 | 2.1110 USD |
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 0.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 0.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 3.6 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 50: three or more warnings
- Thin interest cover: operating profit is only -45.1× the interest
- The last full year was a loss
- Total debt has risen three years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 18 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -16.02× | Weak | 14.16× |
| Price / book | 1.06× | Good | 3.5× |
| Price / sales | 8.71× | Weak | 3.33× |
| EV / EBITDA | -7.62× | Weak | 11.19× |
| Free cash flow yield | -7.5% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 76.7% | Good | 54.9% |
| Operating margin | -55.4% | Weak | 5.8% |
| Net margin | -60.9% | Weak | 1.2% |
| Return on equity | -8.1% | Weak | 4.4% |
| Return on assets | -4% | Weak | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | -45.1% | Weak | 10.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.02× | Good | 0.4× |
| Interest cover | -45.12× | Weak | 2.17× |
| Current ratio | 8.55× | Good | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
| Payout of free cash flow (3 years) | 0% | Weak | — |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow BNTX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.